

## **UBX1967**

**Name:** UBX1967

**Synonyms:** UBX-1967

**Indication:** age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy

**Company:** UNITY Biotechnology

UBX1967 is being evaluated for the potential treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy.

UBX1967, a potent senolytic small molecule inhibitor of particular members of the Bcl-2 family of apoptosis regulatory proteins, targets proteins senescent cells rely on for survival. UNITY plans to submit an IND application in the second half of 2019 for UBX1967. UNITY entered into a license agreement with Ascentage Pharma Group Corp Limited "Ascentage Pharma" in January 2019 granting UNITY exclusive worldwide development and commercialization rights and non-exclusive manufacturing rights outside of Greater China for UBX1967 in all non-oncology indications. Inside Greater China, UNITY is obligated to commercialize UBX1967 through a joint venture with Ascentage Pharma.